Researchers have mapped how propofol, a widely used anesthetic, alters brain connectivity to induce unconsciousness. Using fMRI, they found that propofol disrupts connections in the thalamus, reducing complex information processing and limiting sensory integration.

Researchers uncovered a promising approach to treating Alzheimer’s disease by using dopamine to enhance brain enzyme activity that reduces harmful plaques. Conducted on mice, the study shows that dopamine increases neprilysin production, which breaks down beta-amyloid plaques linked to Alzheimer's.

Researchers have found that antioxidants from Ecklonia cava, a type of seaweed, may help prevent Parkinson's disease by protecting dopamine-producing neurons. In mouse models, these antioxidants restored motor function and improved gut health after exposure to toxins. Cellular studies revealed that these compounds activate the AMPK enzyme and reduce harmful reactive oxygen species, potentially offering a new approach to combat neurodegeneration. This discovery highlights the potential of Ecklonia cava as a preventive ingredient against Parkinson's disease.

Researchers genetically engineered the parasite Toxoplasma gondii to deliver drugs across the blood-brain barrier. This innovative approach has been used to deliver therapeutic proteins to neurons, showing promise for treating neurological conditions like Rett syndrome. The research highlights the potential for parasites to act as delivery vehicles for large molecules that typically struggle to penetrate the brain. This breakthrough could lead to new treatments for a variety of neurological disorders.

A new drug, PIPE-307, shows promise in reversing multiple sclerosis (MS) damage by promoting myelin regeneration around nerve cells, potentially restoring movement and function. Developed by researchers, this innovative therapy targets a specific receptor, M1R, and has already demonstrated success in animal models. PIPE-307 is currently in Phase II clinical trials, offering hope for a groundbreaking treatment that could stop and even heal the damage caused by MS. This novel approach could transform the future of MS therapy by addressing both symptoms and underlying damage.

A new experimental cancer drug could ease cognitive difficulties for those with Rett syndrome, a rare autism-linked disorder, by enhancing brain cell functions. The drug, ADH-503, improves the activity of microglia, which are crucial for maintaining neural networks.